OKYO Pharma (OKYO) Liabilities and Shareholders Equity (2021 - 2025)

OKYO Pharma (OKYO) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $4.6 million in Q3 2025.

• Liabilities and Shareholders Equity for Q3 2025 came in at $4.6 million, up 64.16% year-over-year; the trailing twelve-month figure through Sep 2025 was $12.7 million (up 6.19% YoY), and the FY2025 annual result was $3.7 million, up 138.59% from the prior year.
• Liabilities and Shareholders Equity improved to $4.6 million in Q3 2025 per OKYO's latest filing, from $3.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $7.1 million in Q1 2021 and troughed at $1.5 million in Q1 2024.
• A 5-year average of $4.0 million and a median of $4.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity tumbled 70.38% in 2024, then soared 138.59% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $7.1 million in 2021, then sank by 39.35% to $4.3 million in 2022, then sank by 44.72% to $2.4 million in 2023, then rose by 19.0% to $2.8 million in 2024, then jumped by 64.16% to $4.6 million in 2025.
• Business Quant data shows OKYO's Liabilities and Shareholders Equity at $4.6 million in Q3 2025, $3.7 million in Q1 2025, and $2.8 million in Q3 2024.